Panome Bio, a multi-omics contract research organization (CRO), has unveiled its exposomics service platform designed to offer detailed chemical exposure profiling in biological samples. This innovative service combines two complementary workflows: Discovery Exposomics, which utilizes the company’s MassID™ computational engine for untargeted LC/MS data analysis and a comprehensive database of 32,000 compounds for broad exposure profiling, and Targeted Exposomics, which quantifies 235 priority chemicals using calibrated reference standards in a CLIA laboratory setting.
Environmental exposures from substances such as PFAS, pesticides, and microplastic metabolites are estimated to account for 70–90% of chronic disease risk, yet these factors remain significantly under-measured in health outcome studies. While advancements in genomics have enhanced our understanding of disease susceptibility, they often fail to capture the complex interplay of chemical exposures that contribute to disease variability. According to Panome Bio, this oversight represents a critical gap in current research methodologies.
As the chemical exposure landscape is highly intricate, with thousands of compounds entering the body through various routes, measuring these exposures necessitates a specialized platform. The implications for clinical trials are profound; inter-patient variability in drug response may be influenced by unmeasured chemical exposures, which can affect drug metabolism and treatment outcomes. By integrating exposomics into clinical research, Panome Bio aims to provide a new perspective on trial failures and patient responses, ultimately enhancing the efficacy of drug development strategies.
In the words of Edward Weinstein, CEO of Panome Bio, while significant resources are allocated to understanding the genome and proteome, the chemical environment that patients bring into trials has largely been overlooked. The introduction of exposomics as a tool for patient stratification and variability explanation in drug response underscores its potential to revolutionize clinical research and improve therapeutic outcomes.
Get started today with Solo access →
